IP Library Granted Patent US 9,750,696
Granted Patent B2
US 9,750,696 · App. 14/236,162 · Granted Sep 5, 2017

Dissolution enhanced controlled drug delivery system for poorly water soluble drugs

Inventors: Sandeep Kumar Vats (Sonipat, IN); Kalaiselvan Ramaraju (Tiruchirappalli, IN); Romi Barat Singh (Benares, IN)
Assignee: Sun Pharmaceutical Industries Limited
A61K9/146A61K9/1635A61K9/1641A61K9/2013A61K9/2027A61K9/2031A61K9/2045A61K9/2866A61K9/4808A61K9/5042A61K9/5078A61K31/41A61K31/546A61K9/5047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,696
App. No.
14/236,162
Granted
Sep 5, 2017
Kind
B2
Abstract

The present invention relates to controlled-release pharmaceutical dosage forms comprising a solid dispersion of a poorly water-soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled-release dosage forms.

Claims (14)

1. A controlled-release pharmaceutical dosage form of a poorly water-soluble or insoluble drug comprising the solid dispersion of said drug, one or more of controlled-release material to slow the release of the drug, and one or more of pharmaceutically acceptable excipients; wherein the said solid dispersion comprises the said drug dispersed in polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer in a ratio of drug to graft copolymer at a weight by weight ratio of from 1:1 to 1:5.

2. The controlled-release pharmaceutical dosage form of claim 1 , wherein the dosage form is a matrix-type dosage form or a reservoir-type dosage form.

3. The controlled-release pharmaceutical dosage form of claim 1 , wherein the dosage form is in the form of hard or soft gelatin capsules, tablets, capsules, caplets, pills, granules or mini-tablets.

4. The controlled-release pharmaceutical dosage form of claim 1 , wherein the controlled-release material comprises hydrophilic polymers, hydrophobic polymers, water-swellable polymers, hydrophobic materials, or mixtures thereof.

5. The controlled-release pharmaceutical dosage form of claim 4 , wherein the amount of the controlled-release material comprises from about 2% to about 95% by weight of the dosage form.

6. The controlled-release pharmaceutical dosage form of claim 1 , wherein the pharmaceutically acceptable excipients comprise one or more of binders, fillers/diluents, disintegrants, anti-adherents, lubricants/glidants, plasticizers, coloring agents and flavoring agents.

7. A process for the preparation of a controlled-release pharmaceutical dosage form of a poorly water-soluble or insoluble drug comprising the solid dispersion of said drug, one or more of controlled-release material to slow the release of the drug, and one or more of pharmaceutically acceptable excipients; wherein the said solid dispersion comprises said drug dispersed in polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer in a ratio of drug to graft copolymer at a weight by weight ratio of from 1:1 to 1:5; and wherein the process includes combining the solid dispersion, the controlled-release material and pharmaceutically acceptable excipient and processing into the dosage form using appropriate toolings.

8. The controlled-release pharmaceutical dosage form of claim 1 , wherein the controlled-release material slows the release of the drug to provide for release in a continuous manner.

9. The controlled-release pharmaceutical dosage form of claim 8 , wherein the controlled-release material releases the drug to provide for absorption in a continuous manner.

10. The controlled-release pharmaceutical dosage form of claim 7 , wherein the controlled-release material slows the release of the drug to provide for release in a continuous manner.

11. The controlled-release pharmaceutical dosage form of claim 10 , wherein the controlled-release material releases the drug to provide for absorption in a continuous manner.

12. The controlled-release pharmaceutical dosage form of claim 2 , wherein the dosage form is a reservoir-type dosage form comprising a core and a controlled release coating, and the core comprises the drug and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

13. The controlled-release pharmaceutical dosage form of claim 12 , wherein the controlled release coating comprises a polymer.

14. The controlled-release pharmaceutical dosage form of claim 13 , wherein the polymer comprises one or more of cellulose acetate, ethyl cellulose, polyamide, polyethylene, polyethylene terephthalate, polypropylene polyurethane, polyvinyl acetate, polyvinyl chloride, polyhydroxybutyrate, polyhydroxyvalerate, ethylene vinyl acetate copolymers, styrene-butadienestyrene copolymers, styrene-isoprene-styrene copolymers, and polylactic acid, polyglycolic acid and copolymers thereof, and mixtures thereof.

Assignments (2)
MERGER Recorded Jan 13, 2016
From: RANBAXY LABORATORIES LIMTED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 037513/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2014
From: VATS, SANDEEP KUMAR; KALAISELVAN, RAMARAJU; SINGH, ROMI BARAT
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 032170/0315 →
Priority Claims (1)
IN 2175/DEL/2011 · Aug 1, 2011 · national
Continuity (1)
Related Publication 20150174071A1 · Jun 25, 2015